Fig. 1 · Structure

Documents & Downloads

Captopril

Cat. No. A11738 CAS 62571-86-2
Captopril is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Captopril Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Captopril from 3 published references. In vitro models include HUVECs. In vivo models include CTR mice; UM‐HET3 mice.

Captopril In Vitro Studies

HUVECs were treated with Captopril in culture medium. qPCR analysis showed that Captopril did not alter Sp1 and Sp3 mRNA levels. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Captopril leaves Sp1 and Sp3 transcript levels unchanged

Cell-based study · HUVECs [1]

HUVECs received Captopril at 10 μmol/L in culture medium. Captopril did not alter Sp1 and Sp3 mRNA levels, assessed by qPCR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
qPCR analysis of Sp1 and Sp3 mRNA levelsReported result Captopril did not alter Sp1 and Sp3 mRNA levels[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μmol/L
Method
in culture medium
Reported limits
Not stated in the sentences used: schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Captopril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Captopril activates Sp1 and Sp3 via bradykinin B1 receptor (S90); Methods > Cell culture and treatments (S149); Fig. 7 legend (S396)

qPCR analysis of Sp1 and Sp3 mRNA levels: qPCR analysis of Sp1 and Sp3 mRNA levels — Results > Captopril activates Sp1 and Sp3 via bradykinin B1 receptor (S90); Fig. 7 legend (S396)

Captopril In Vivo Studies

In vehicle-controlled comparisons, Captopril lowered blood pressure and improved endothelium-dependent relaxation of mesenteric resistance arteries in CTR, but not dKO mice. In UM‐HET3 mice, Captopril mixed with chow increased median lifespan by 6% in females and 13% in males when data were pooled across sites. In spontaneously hypertensive rats, Captopril administered in drinking water returned final SBP to normal values, reaching 138 ± 0.8 mm Hg. [1,2,3]

Captopril lowered blood pressure in CTR, but not dKO mice

Animal study · CTR mice [1]

CTR or dKO mice were administered captopril (10 mg/kg body weight) or vehicle via intraperitoneal injection per day for 4 weeks. Captopril lowered blood pressure and improved endothelium-dependent relaxation of mesenteric resistance arteries from CTR, but not dKO mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SBP and MBPReported result 10 mg/kg body weight via intraperitoneal injection per day for 4 weeks: Captopril lowered blood pressure and improved endothelium-dependent relaxation of mesenteric resistance arteries from CTR, but not dKO mice.[1]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
per day for 4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Captopril 10 mg/kg body weightvehicle10 mg/kg body weight via intraperitoneal injection per day for 4 weeks: Captopril lowered blood pressure and improved endothelium-dependent relaxation of mesenteric resistance arteries from CTR, but not dKO mice.[1]
Captopril 10 mg/kg body weight
Model: CTR mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Captopril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Endothelial Sp1 and Sp3 are implicated in the effects of captopril (S75); Methods > Animals (S164, S165, S168); Fig. 6 legend (S379)

SBP and MBP: SBP and MBP; comparator: vehicle — Results > Endothelial Sp1 and Sp3 are implicated in the effects of captopril (S75); Methods > Animals (S168); Fig. 6 legend (S379)

Captopril 10 mg/kg body weight · Results > Endothelial Sp1 and Sp3 are implicated in the effects of captopril (S75); Methods > Animals (S168)

Captopril increases median lifespan in mice

Animal study · UM‐HET3 mice [2]

UM‐HET3 mice received Captopril at 180 ppm mixed with chow beginning at 5 months of age, with chow without additives as the control. In data pooled across all sites, median lifespan increased in females by 6% (p = 0.002) and in males by 13% (p = 0.001).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
median lifespanmedian lifespan increased the median lifespan in females by 6% (p = 0.002) and in males by 13% (p = 0.001)[2]

Conditions shared by the study groups

Route
mixed with chow
Treatment course
fed to mice beginning at 5 months of age
Vehicle
Purina 5LG6
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Captopril 180 ppmPurina 5LG6 without additivesincreased the median lifespan in females by 6% (p = 0.002) and in males by 13% (p = 0.001) when data were pooled across all three sites[2]
Captopril 180 ppm
Model: UM‐HET3 mice
Methods and source locations

Compound reported in the paper: Captopril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Standard analysis (S10, S20); EXPERIMENTAL PROCEDURES > Animals (S65, S71); EXPERIMENTAL PROCEDURES > Control and experimental diets (S90, S91)

median lifespan: median lifespan; comparator: Purina 5LG6 without additives — RESULTS > Standard analysis (S20)

Captopril 180 ppm · RESULTS > Standard analysis (S20); EXPERIMENTAL PROCEDURES > Control and experimental diets (S91)

Captopril restores systolic blood pressure in hypertensive rats

Animal study · spontaneously hypertensive rats (SHR) aged 18-20 weeks; six animals each [3]

Spontaneously hypertensive rats received Captopril at 80 mg/kg/day in drinking water for 12 weeks, with untreated rats as controls. Final SBP returned to normal values, at 138 ± 0.8 mm Hg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Final SBP (mm Hg)Final SBP 138 ± 0.8 mm Hg[3]

Conditions shared by the study groups

Route
dissolved in the drinking water
Treatment course
during 12 weeks
Vehicle
drinking water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Captopril 80 mg/kg/daySHR (untreated)reversed these parameters back to normal values in SHR; 138 ± 0.8 mm Hg[3]
Captopril 80 mg/kg/day
Model: spontaneously hypertensive rats (SHR) aged 18-20 weeks; six animals each
Methods and source locations

Compound reported in the paper: Captopril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals, treatments, heart tissue sampling and measurements in plasma (S2, S5, S6); Results > Body weight, left ventricle weight, blood pressure and heart rate (S55); Table 1 (T1.h1, T1.r4)

Final SBP (mm Hg): Final SBP (mm Hg); comparator: SHR (untreated) — Results > Body weight, left ventricle weight, blood pressure and heart rate (S55); Table 1 (T1.h1, T1.r4)

Captopril 80 mg/kg/day · Methods > Animals, treatments, heart tissue sampling and measurements in plasma (S6); Results > Body weight, left ventricle weight, blood pressure and heart rate (S55); Table 1 (T1.h1, T1.r4)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 62571-86-2
Formula C9H15NO3S
Molecular Weight 217.3
Synonyms Capoten
SMILES
C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 41 mg/mL (188.69 mM)
Water 2 mg/mL (9.2 mM)
Ethanol 41 mg/mL (188.69 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Captopril Research References

  1. [1] Lu H, Jiang X, He L, et al. Endothelial Sp1/Sp3 are essential to the effect of captopril on blood pressure in male mice. Nat Commun (2023). PMID: 37735515 DOI: 10.1038/s41467-023-41567-1 Source material
  2. [2] Strong R, Miller RA, Cheng CJ, et al. Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice. Aging Cell (2022). PMID: 36179270 DOI: 10.1111/acel.13724 Source material
  3. [3] Miguel-Carrasco JL, Zambrano S, Blanca AJ, et al. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) (2010). PMID: 20462420 DOI: 10.1186/1476-9255-7-21 Source material

Added to your cart

View Cart Checkout
Loading...